87. Pulmonary veno-occlusive disease Clinical trials / Disease details

Clinical trials : 3 / Drugs : 4 - (DrugBank : 3) / Drug target genes : 4 - Drug target pathways : 45

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000020543	2015/03/01	13/01/2016	Efficacy of imatinib for the treatment of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis	Efficacy of imatinib for the treatment of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis - Efficacy of imatinib for the treatment of pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis	pulmonary veno-occlusive disease/pulmonary capillary hemangiomatosis	Oral administration of imatinib	National Hospital Organization Okayama Medical Center	NULL	Complete: follow-up complete	18years-old	Not applicable	Male and Female	8	Not applicable	Japan
2	NCT00891527 (ClinicalTrials.gov)	October 2008	30/4/2009	Pilot Study Using Avastin and Gleevec to Treat the Progression of Intraluminal Pulmonary Vein Stenosis	Adjunct Targeted Biologic Inhibition in Children With Multivessel Intraluminal Pulmonary Vein Stenosis	Pulmonary Veno Occlusive Disease	Drug: Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)	Boston Children's Hospital	NULL	Completed	N/A	N/A	All	50	Phase 1/Phase 2	United States
3	NCT00563498 (ClinicalTrials.gov)	July 2004	21/11/2007	Effects on Glutamine on the Outcome of Allogeneic Bone Marrow Transplant Recipients	A Randomized Control Studies on the Effects of Glutamine on the Clinical Outcome of Bone Marrow Transplant Recipients With Special Reference to Veno-occlusive Disease and Mucositis.	Pulmonary Veno-Occlusive Disease;Hepatic Veno-Occlusive Disease;Mucositis	Drug: Glutamine	Hospital Authority, Hong Kong	The University of Hong Kong;Fresienius Kabi HK Ltd	Recruiting	18 Years	N/A	Both	40	N/A	China